Currently, no specific laboratory monitoring is required, though tracking inflammatory markers can provide objective evidence of therapeutic effect
1419, PL-10, PLD-116, PL 14736), in trials for inflammatory bowel disease (LD1 not achieved), wound and fistulas treatment (1-7, 27, 29, 33-37) (i.e., stimulation of expression of the early growth response 1 (egr-1) gene (38), and other molecular pathways (38-42), effective alone without carrier (1-7) it has a particular effect on endothelium protection along with prominent angiogenesis (1, 43-47) and an effect on NO-system (1-7)
Concerns about IGF-1 include potential effects on cancer risk, acromegalic changes with chronic elevation, and metabolic disruption
New Biotechnol
Vaquero-Siguero, N